NEU 2.38% $12.70 neuren pharmaceuticals limited

NEU is materially undervalued, page-5

  1. 1,255 Posts.
    lightbulb Created with Sketch. 317
    are there any neuroscience drugs out there which have been successful in phase 2 across 3 different indications? Accordingly to Matt McNamara, from Horizon 3 heathcare “It is unheard of to have positive data from three rare paediatric disorders for one compound.”
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.